Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

mplied discussions regarding the potential development and marketing of potential future respiratory products, regarding potential future launches of indacaterol, or regarding potential future revenues from indacaterol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will successfully develop or bring to market any additional respiratory products.  Nor can there be any guarantee that indacaterol will be launched in any particular countries, or at any particular time.  Neither can there be any guarantee that indacaterol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding indacaterol could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including unexpected reimbursement difficulties or delays; competition in general; government, industry and general public pricing pressures; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... at 10 a.m. (Eastern Time) on Thursday, April 23, 2015, ... Investors and other interested parties may ... the Company,s website at www.jnj.com and clicking on ... the meeting will be made available a few hours after ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the reporting of data from ... Hydrochloride for Injection with the Delcath Hepatic Delivery ... presentation at the Society of Surgical Oncology (SSO) ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... ), the leading source of health information, ... on the new National Action Plan ... interview, President Obama emphasized the urgency and ... impact on national and global health.    ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Minocycline Showed Substantial,Reduction of Disease Activity in ... Treatment With Antibiotic Further Reduced Brain,Lesions and ... May 4, 2007 - New data from ... of Copaxone,(glatiramer acetate injection) along with the ...
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
Cached Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4
(Date:3/27/2015)... 2015 Ticket Down is a reputable source ... in Omaha, Nebraska on Friday, May 8th and Saturday, ... dates will be added in Omaha as Garth has done ... The Garth Brooks World Tour is continuing its run throughout ... Garth Brooks and Trisha Yearwood will bring their act to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... Irvine, CA (PRWEB) March 27, 2015 ... nation’s leading providers of business support services to dental ... opening of an affiliated Castle Dental office ... Lake Blvd. Hendersonville, TN 37075, this new Castle Dental ... they can receive the latest in comprehensive, quality dental ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Gardner HealthDay Reporter , TUESDAY, May 3 (HealthDay ... to deployment or who,ve been injured during combat are more ... home. The PTSD tends to be worse with more ... of the Archives of General Psychiatry . The ...
... drug selectively kills the cancerous cells that cause chronic ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James). The study shows that ... lymphocytes that cause chronic lymphocytic leukemia (CLL). , ...
... or emergency medical technician providing first aid with a ... bleeding, fights bacteria (and other sources of infection), stimulates ... it is quickly absorbed by surrounding tissue may ... Or, imagine diabetics with hard-to-heal wounds finding a source ...
... develop a pioneering tool to help tailor the treatment of ... a new EU project. The 5-year AirPROM* project, which ... and physical models of the whole airways system, to help ... treatments. The news comes on World Asthma Day ...
... -- Few Americans bother to read the labels on over-the-counter ... drugs, ingredients, a new study says. This lack of ... a leading cause of acute liver failure in the United ... Acetaminophen, the active ingredient in Tylenol, is in more ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
Cached Medicine News:Health News:Military Personnel With Mental Woes Before Deployment at Higher PTSD Risk 2Health News:Agent selectively targets malignant B cells in chronic leukemia, study shows 2Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 2Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 3Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 4Health News:Virtual lung models set to personalize asthma and COPD treatment 2Health News:Many Consumers Don't Know What's in Over-the-Counter Painkillers: Study 2Health News:Chest journal news briefs, May 2011 issue 2
... fits almost any arm -- simply bend the ... exact requirements. The cuffs are connected by an ... almost any elbow angle. The central part of ... contacts the elbow joint.,Special attention is paid to ...
... ankle splint may be used for either ... It is effective in stabilizing the ... after cast removal. The rigid pre-bent ... side-to-side support. The stays also help ...
... lightweight AFO is designed to assist ambulation ... neurological deficit resulting in drop-foot. The anatomically ... shoes. It is fabricated from specially formed ... term performance and reliability. For a more ...
... The VacoSplint has a rigid shell with a ... immobilized foot/ankle. The VacoSplint is a non-weight bearing ... bear he/she should transfer to the STORM walker ... the nylon liner from the STORM and insert ...
Medicine Products: